This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Drugs Remove Genotype Remove In-Vivo Remove Protein
article thumbnail

Innovative Companies Diving into The Neuro Market Ahead of 2021

The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. which will remain a key shareholder. SciNeuro Pharmaceuticals. in a statement. .

Marketing 52
Marketing In-Vivo Protein In-Vitro 52
article thumbnail

RNA editing oligonucleotide selected for AATD treatment 

Drug Discovery World

DECEMBER 12, 2023

I look forward to having access to this therapy as quickly as possible.” I look forward to having access to this therapy as quickly as possible.” The post RNA editing oligonucleotide selected for AATD treatment appeared first on Drug Discovery World (DDW).

RNA 52
RNA In-Vivo Genotype Genetics 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024